HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


CFSAN science review finds lean operation

This article was originally published in The Rose Sheet

Executive Summary

The laboratory infrastructure within FDA's Center for Food Safety and Applied Nutrition is stretched thin with minimal administrative support and little flexibility, according to an interim research review report presented by an FDA Science Board subcommittee. "There's not as much of a support system within CFSAN," said subcommittee member Rhona Applebaum during the Feb. 22 Science Board meeting in Bethesda, Md. "Oftentimes what we saw and what we heard is we're asking our chefs to be also the chief cooks and bottle washers." Applebaum added that the food center is stretched thin performing crucial tasks to protect public health. The CFSAN research subcommittee plans to continue reviewing CFSAN activities and will present its final report during a May 17 Science Board meeting. The Obama administration has proposed a 32.9 percent increase in FDA food program funding, to $1.04 billion, for fiscal 2011 (1"The Rose Sheet" Feb. 8, 2010)

You may also be interested in...

FDA Requests $9 Mil. To Educate Consumers On AE Cosmetics Reporting

The Center for Food Safety and Applied Nutrition has requested approximately $9 million for fiscal 2011 to raise consumer awareness of its adverse events reporting program for cosmetics, according to FDA budget documents

QUOTED. 11 May 2021. Phil Brown.

The MHRA is in listening mode as it gathers feedback to shape the UKCA marking for medical devices. See what Phil Brown, regulatory director of the Association of British HealthTech Industries, said about it here.

Fixed Combinations Of ‘Old Antibiotic’ Plus New Moiety Eligible For NCE Exclusivity, US FDA Says

A 2008 law that limited exclusivity for certain antibiotics to three years does not apply to Allergan’s Avycaz, which combines an approved old antibiotic active moiety and a new active moiety, CDER exclusivity board concludes.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts